Approach to Expression of COX-2 mRNAs in Endometriosis Tissues and Its Mechanism

In: Journal of Practical Obstetrics and Gynecology · 2005 · W2367427966
article OA: closed CC0
View on OpenAlex
AI-generated summary by gemini-2.5-flash-lite, 2026-07-14

This study found significantly increased cyclooxygenase-2 (COX-2) mRNA expression in endometriosis tissues compared to normal controls in both proliferative and secretory phases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Objective: To investigate the expression of cyclooxygenase-2 (COX-2) mRNA in endometriosis tissues, and to approach its role in the pathogenesis of endometriosis. Methods: Endometrial specimens were obtained from 38 cases in endometriosis and 35 normal women for controls. Expression of COX-2 mRNAs was examined by in situ hybridization technique with specific cDNA probes. Results: COX-2 mRNA mainly expressed in plasma of glandular cell and rarely located in nucleus. In endometriosis cases, expression of COX-2 mRNA increased in proliferative phase(3.11±0.56)and secretory phase (3.05±0.41) , and were significantly higher than normal controls with the same phase, respectively (P0.01). There was no difference of COX-2 mRNA expression between proliferative and secretory endometrium in endometriosis group (P0.05). Conclusions: The increased expression of COX-2 mRNAs in endometriosis may be one of the pathogenesis of endometriosis, and it's possible to provide a new target for therapy of endometriosis in the further research to COX-2.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK